Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Australia: These 48 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Australia: These 48 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can AXUMIN (fluciclovine f-18) generic drug versions launch in Australia?

Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Australia Patent 2,006,319,987
Patent Title: Precursor compound of radioactive halogen labeled organic compound

AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug. There has been litigation on patents covering AXUMIN

The generic ingredient in AXUMIN is fluciclovine f-18. Additional details are available on the fluciclovine f-18 profile page.

When can ZTALMY (ganaxolone) generic drug versions launch in Australia?

Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Australia Patent 2,006,318,349

ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Australia?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Australia Patent 2,007,328,945

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can LETAIRIS (ambrisentan) generic drug versions launch in Australia?

Generic name: ambrisentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Australia Patent 2,007,333,115
Patent Title: Composition for treating a pulmonary hypertension

LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LETAIRIS

See drug price trends for LETAIRIS.

The generic ingredient in LETAIRIS is ambrisentan. Additional details are available on the ambrisentan profile page.

When can VYKAT XR (diazoxide choline) generic drug versions launch in Australia?

Generic name: diazoxide choline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: Australia Patent 2,006,335,153

VYKAT XR is a drug marketed by Soleno. There are six patents protecting this drug. There has been litigation on patents covering VYKAT XR

The generic ingredient in VYKAT XR is diazoxide choline. Additional details are available on the diazoxide choline profile page.

When can SEYSARA (sarecycline hydrochloride) generic drug versions launch in Australia?

Generic name: sarecycline hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2026
Generic Entry Controlled by: Australia Patent 2,007,338,681
Patent Title: Substituted tetracycline compounds for treatment of inflammatory skin disorders

SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.

See drug price trends for SEYSARA.

The generic ingredient in SEYSARA is sarecycline hydrochloride. Additional details are available on the sarecycline hydrochloride profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in Australia?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Australia Patent 2,008,211,554

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in Australia?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Australia Patent 2,008,211,981

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Australia?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Australia Patent 2,008,218,595

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Australia?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Australia Patent 2,008,218,595

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can PRESTALIA (amlodipine besylate; perindopril arginine) generic drug versions launch in Australia?

Generic name: amlodipine besylate; perindopril arginine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 26, 2027
Generic Entry Controlled by: Australia Patent 2,007,220,435

PRESTALIA is a drug marketed by Adhera. There is one patent protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering PRESTALIA

The generic ingredient in PRESTALIA is amlodipine besylate; perindopril arginine. Additional details are available on the amlodipine besylate; perindopril arginine profile page.

When can SPRAVATO (esketamine hydrochloride) generic drug versions launch in Australia?

Generic name: esketamine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Australia Patent 2,007,229,866
Patent Title: Intranasal administration of ketamine to treat depression

Drug Price Trends for SPRAVATO
SPRAVATO is a drug marketed by Janssen Pharms. There are seven patents protecting this drug. There has been litigation on patents covering SPRAVATO

See drug price trends for SPRAVATO.

The generic ingredient in SPRAVATO is esketamine hydrochloride. Additional details are available on the esketamine hydrochloride profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Australia?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Australia Patent 2,008,229,609

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can EDARBI (azilsartan kamedoxomil) generic drug versions launch in Australia?

Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Australia Patent 2,008,235,790
Patent Title: Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent

Drug Price Trends for EDARBI
EDARBI is a drug marketed by Azurity. There is one patent protecting this drug. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. Additional details are available on the azilsartan kamedoxomil profile page.

When can INLYTA (axitinib) generic drug versions launch in Australia?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Australia Patent 2,008,236,444

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch in Australia?

Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: Australia Patent 2,008,234,098

Drug Price Trends for QVAR REDIHALER
QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. Additional details are available on the beclomethasone dipropionate profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Australia?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Australia Patent 2,007,352,608

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Australia?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Australia Patent 2,012,201,288

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Australia?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Australia Patent 2,014,202,367

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Australia?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Australia Patent 2,016,202,063

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Australia?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: Australia Patent 2,007,249,924

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Australia?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Australia Patent 2,008,249,772

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Australia?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Australia Patent 2,008,252,931

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Australia?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Australia Patent 2,008,259,411

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Australia?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Australia Patent 2,008,259,411

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in Australia?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Australia Patent 2,008,265,721
Patent Title: Synthetic bile acid composition, method, and preparation

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can CARDAMYST (etripamil) generic drug versions launch in Australia?

Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: Australia Patent 2,008,266,798
Patent Title: Short acting phenylalkylamine calcium channel blockers and uses thereof

Drug Price Trends for CARDAMYST
CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.

When can JESDUVROQ (daprodustat) generic drug versions launch in Australia?

Generic name: daprodustat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 22, 2027
Generic Entry Controlled by: Australia Patent 2,007,260,837
Patent Title: Prolyl hydroxylase inhibitors

JESDUVROQ is a drug marketed by Glaxosmithkline. There are six patents protecting this drug.

See drug price trends for JESDUVROQ.

The generic ingredient in JESDUVROQ is daprodustat. Additional details are available on the daprodustat profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in Australia?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Australia Patent 2,007,274,054
Patent Title: Short-acting benzodiazepine salts and their polymorphic forms

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can TWIRLA (ethinyl estradiol; levonorgestrel) generic drug versions launch in Australia?

Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Australia Patent 2,008,275,101

Drug Price Trends for TWIRLA
TWIRLA is a drug marketed by Agile. There are three patents protecting this drug. Two tentatively approved generics are ready to enter the market.

See drug price trends for TWIRLA.

The generic ingredient in TWIRLA is ethinyl estradiol; levonorgestrel. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Australia?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Australia Patent 2,008,274,534
Patent Title: Pyrimidinyl pyridazinone derivates

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Australia?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Australia Patent 2,008,274,670
Patent Title: Pyridazinone derivates

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in Australia?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: Australia Patent 2,008,276,842

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can RASUVO (methotrexate) generic drug versions launch in Australia?

Generic name: methotrexate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Australia Patent 2,007,276,387

Drug Price Trends for RASUVO
RASUVO is a drug marketed by Medexus. There is one patent protecting this drug. There has been litigation on patents covering RASUVO

See drug price trends for RASUVO.

The generic ingredient in RASUVO is methotrexate. Additional details are available on the methotrexate profile page.

When can MULPLETA (lusutrombopag) generic drug versions launch in Australia?

Generic name: lusutrombopag
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 31, 2027
Generic Entry Controlled by: Australia Patent 2,008,283,357

MULPLETA is a drug marketed by Vancocin Italia. There are three patents protecting this drug.

See drug price trends for MULPLETA.

The generic ingredient in MULPLETA is lusutrombopag. Additional details are available on the lusutrombopag profile page.

When can SALONPAS (menthol; methyl salicylate) generic drug versions launch in Australia?

Generic name: menthol; methyl salicylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 01, 2027
Generic Entry Controlled by: Australia Patent 2,007,279,643
Patent Title: Adhesive preparation

SALONPAS is a drug marketed by Hisamitsu Pharm Co. There are two patents protecting this drug.

The generic ingredient in SALONPAS is menthol; methyl salicylate. Additional details are available on the menthol; methyl salicylate profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Australia?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Australia Patent 2,008,285,784
Patent Title: Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in Australia?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: Australia Patent 2,008,286,651
Patent Title: DHEA compositions for treating menopause

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can BRILINTA (ticagrelor) generic drug versions launch in Australia?

Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 20, 2027
Generic Entry Controlled by: Australia Patent 2,007,288,541

Drug Price Trends for BRILINTA
BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. Additional details are available on the ticagrelor profile page.

When can BRILINTA (ticagrelor) generic drug versions launch in Australia?

Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 20, 2027
Generic Entry Controlled by: Australia Patent 2,011,205,164

Drug Price Trends for BRILINTA
BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. Additional details are available on the ticagrelor profile page.

When can VIZAMYL (flutemetamol f-18) generic drug versions launch in Australia?

Generic name: flutemetamol f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 30, 2027
Generic Entry Controlled by: Australia Patent 2,008,292,201

VIZAMYL is a drug marketed by Ge Healthcare. There is one patent protecting this drug.

See drug price trends for VIZAMYL.

The generic ingredient in VIZAMYL is flutemetamol f-18. Additional details are available on the flutemetamol f-18 profile page.

When can TYMLOS (abaloparatide) generic drug versions launch in Australia?

Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2027
Generic Entry Controlled by: Australia Patent 2,007,322,334
Patent Title: Method of drug delivery for bone anabolic protein

Drug Price Trends for TYMLOS
TYMLOS is a drug marketed by Radius. There are nine patents protecting this drug. There has been litigation on patents covering TYMLOS

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. Additional details are available on the abaloparatide profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in Australia?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 09, 2027
Generic Entry Controlled by: Australia Patent 2,006,325,244
Patent Title: Therapeutic compositions comprising ingenol-3-angelate

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Australia?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Australia Patent 2,008,322,963
Patent Title: Pharmaceutical compositions

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Australia?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: Australia Patent 2,010,210,018

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Australia?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: Australia Patent 2,010,210,019

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in Australia?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: Australia Patent 2,008,326,297
Patent Title: Antibacterial aminoglycoside analogs

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Australia?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Australia Patent 2,008,329,673

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Australia?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Australia Patent 2,009,289,647

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Australia?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Australia Patent 2,008,329,673

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Australia?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Australia Patent 2,009,289,647

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in Australia?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: Australia Patent 2,008,333,811

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can AMVUTTRA (vutrisiran) generic drug versions launch in Australia?

Generic name: vutrisiran
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: Australia Patent 2,008,340,354

AMVUTTRA is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering AMVUTTRA

See drug price trends for AMVUTTRA.

The generic ingredient in AMVUTTRA is vutrisiran. Additional details are available on the vutrisiran profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in Australia?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: Australia Patent 2,007,328,008
Patent Title: Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Australia?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Australia Patent 2,008,333,845

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in Australia?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Australia Patent 2,008,340,101

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in Australia?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Australia Patent 2,015,200,801

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can RYTARY (carbidopa; levodopa) generic drug versions launch in Australia?

Generic name: carbidopa; levodopa
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 28, 2027
Generic Entry Controlled by: Australia Patent 2,008,343,787
Patent Title: Controlled release formulations of levodopa and uses thereof

RYTARY is a drug marketed by Impax. There are eight patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering RYTARY

See drug price trends for RYTARY.

The generic ingredient in RYTARY is carbidopa; levodopa. Additional details are available on the carbidopa; levodopa profile page.

Australia Branded and Generic Drug Markets: Regulatory Opportunities, Patent Risk and Commercial Outlook

Last updated: October 12, 2026

Australia is a regulated, reimbursement-driven pharmaceutical market in which TGA approval does not guarantee commercial access. Branded medicines compete for Pharmaceutical Benefits Scheme (PBS) listing, while generic and biosimilar companies compete primarily on price, supply reliability, substitution eligibility and patent timing. The main opportunities are faster TGA pathways, PBS listing of cost-effective medicines, biosimilar substitution, hospital procurement and Asia-Pacific supply-chain positioning. The main challenges are mandatory price disclosure, reference pricing, 60-day dispensing, concentrated wholesaling and pharmacy distribution, patent litigation, and slow reimbursement negotiations.

How large is the Australian branded and generic drug market?

Australia is a high-income pharmaceutical market with public reimbursement accounting for a substantial share of prescription-drug sales. The PBS and Repatriation Pharmaceutical Benefits Scheme together generated approximately A$18 billion in annual expenditure in the 2022-23 period, although the precise commercial market value is higher because it includes private prescriptions, hospital medicines and non-PBS products (Australian Government Department of Health and Aged Care, 2023).

The market has four principal channels:

Channel Main purchaser or payer Commercial characteristics
PBS community medicines Federal government and patients Largest reimbursed outpatient channel; prices are negotiated and reduced through statutory mechanisms
Private prescriptions Patients and private insurers Greater scope for brand differentiation, but high generic substitution pressure
Public hospitals State and territory governments Tender-based procurement; strong pricing and supply requirements
Private hospitals and clinics Hospitals, insurers and patients Relevant for specialty, oncology, infusion and procedural products

Generic medicines account for a large proportion of prescription volumes. Branded products retain a disproportionate share of value in oncology, immunology, rare diseases, vaccines, diabetes, respiratory disease and specialty hospital care.

The commercial distinction between branded and generic drugs is narrowing in several categories. Originator companies increasingly rely on lifecycle management, combination products, devices, patient-support programs and specialty indications. Generic companies are expanding into complex injectables, inhalers, modified-release products and biosimilars, where regulatory and manufacturing barriers are higher.

What is the regulatory pathway for branded and generic drugs in Australia?

The Therapeutic Goods Administration (TGA) regulates the quality, safety and efficacy of medicines. Products generally must be included in the Australian Register of Therapeutic Goods (ARTG) before supply, subject to limited exemptions (Therapeutic Goods Administration, 2024a).

Branded medicines

A new chemical entity generally requires a full registration application supported by clinical, nonclinical, chemistry, manufacturing and controls data. The TGA assesses the product dossier, manufacturing sites, labeling, risk-management information and proposed indications.

Key regulatory routes include:

  • Standard prescription-medicine registration.
  • Priority review for medicines addressing serious conditions with significant unmet need.
  • Provisional approval based on preliminary clinical data, subject to confirmatory evidence.
  • Orphan-drug pathways for medicines targeting rare diseases.
  • Special access and authorised prescriber pathways for unregistered products.
  • Australian reliance and comparable overseas regulator pathways where applicable.

The TGA’s regulatory decision is separate from PBS reimbursement. A product may be registered but commercially limited if the sponsor does not obtain a positive Pharmaceutical Benefits Advisory Committee (PBAC) recommendation or cannot agree on price and risk-sharing terms with the government.

Generic medicines

Generic applicants generally rely on bioequivalence rather than repeating the originator’s full clinical development program. The application must establish pharmaceutical equivalence, bioequivalence, manufacturing quality and appropriate labeling.

The main regulatory barriers are:

  • Demonstrating bioequivalence for complex dosage forms.
  • Establishing equivalence for inhaled, topical, ophthalmic and modified-release products.
  • Validating manufacturing sites and active pharmaceutical ingredient suppliers.
  • Addressing device performance for inhalers, pens and autoinjectors.
  • Avoiding patent infringement.
  • Securing PBS listing and substitutable status.

TGA approval does not automatically establish that a generic is legally safe to launch. Patent clearance remains a separate commercial and litigation question.

How does PBS listing affect branded and generic drug sales?

PBS listing is the central commercial gatekeeper for prescription medicines. PBAC assesses clinical effectiveness, comparative benefit, cost-effectiveness and financial impact. The government then negotiates listing terms, price, volume arrangements and risk-sharing provisions with the sponsor (Australian Government Department of Health and Aged Care, 2024a).

For branded products, the principal risks are:

  • A negative or deferred PBAC recommendation.
  • A requirement for price reduction.
  • Restrictive listing criteria.
  • Comparator-based cost-effectiveness analysis.
  • Budget-impact controls.
  • Delayed negotiations after regulatory approval.
  • Therapeutic substitution by a lower-priced product.

For generics, PBS listing depends on the reference brand, statutory pricing rules and administrative requirements. Once a generic enters a reference-priced group, the sponsor may face rapid price compression.

What is the difference between F1 and F2 PBS pricing?

PBS pricing generally distinguishes between:

  • F1 products, which have no comparable brands or are not subject to brand-level competition.
  • F2 products, which have multiple brands and are subject to price disclosure and price-reduction rules.

When a generic enters a competitive group, the government may reduce the PBS price based on disclosed market prices. This lowers government expenditure but can compress supplier margins and make supply interruptions more likely.

Price disclosure requires suppliers to report effective prices after discounts, rebates and other commercial arrangements. The resulting weighted-average price can trigger statutory PBS reductions. This mechanism creates a recurring downward adjustment rather than a one-time generic price event.

When do branded drugs lose exclusivity in Australia?

Australian exclusivity depends on patents, regulatory data protection, market structure and reimbursement rules.

Protection Typical duration or rule Commercial effect
Standard patent Up to 20 years from filing Protects the claimed invention
Pharmaceutical patent term extension Up to 5 additional years, subject to statutory conditions Extends protection for qualifying pharmaceutical substances
Regulatory data protection Generally 5 years for qualifying new active substances Restricts reliance on specified registration data
Orphan-related protection Depends on the applicable TGA and registration framework Can affect registration and commercial timing
PBS exclusivity No general standalone exclusivity period Listing is exposed to competition after legal protection ends
SPC-like protection No broad European-style supplementary protection certificate Patent term extension is the principal statutory mechanism

Patent term is not equivalent to effective market exclusivity. A patent may expire before a generic launches if other patents remain enforceable. Conversely, a broad-looking patent may be vulnerable to invalidity, non-infringement or lack of support.

The pharmaceutical patent term extension is subject to statutory limits, including the relationship between the extension and the date of first regulatory approval. The extension is not available for every patent covering a medicine and must be assessed claim by claim under the Patents Act 1990 (Cth).

What patents protect prescription drugs in Australia?

Patent protection may cover several layers of a product:

Active ingredient patents

These are usually the strongest early patents. They may protect the chemical compound, stereoisomer, salt, polymorph or crystalline form. Generic entry normally depends on expiry or invalidation of the relevant claims.

Formulation patents

Formulation patents may cover:

  • Extended-release tablets.
  • Injectable suspensions.
  • Liposomal or nanoparticle delivery.
  • Stabilized biologic formulations.
  • Inhaled formulations.
  • Transdermal systems.
  • Device-drug combinations.
  • Specific excipients or concentration ranges.

Formulation patents often become more important after compound-patent expiry. Their enforceability depends on whether the generic product falls within the claim language and whether the claims satisfy novelty, inventive step, support and sufficiency requirements.

Method-of-use patents

Method-of-use claims cover treatment of a disease, patient population, dosing schedule, biomarker-defined group or combination regimen. A generic may seek registration for indications that avoid patented uses, subject to Australian labeling and patent rules.

Skinny-label strategies can reduce infringement exposure, but they require precise control of product information, marketing, medical education and distribution practices. A generic sponsor can face risk if its conduct encourages use for a patented indication despite omission of that indication from the approved label.

Manufacturing patents

Manufacturing patents can cover:

  • Synthesis routes.
  • Intermediates.
  • Purification processes.
  • Cell-culture methods.
  • Conjugation processes.
  • Sterile filling.
  • Crystallization and particle engineering.

These patents may not appear to block product registration, but they can prevent use of a preferred commercial manufacturing route. They are more significant for complex small molecules, peptides, vaccines and biologics.

What is the Orange Book status of medicines in Australia?

Australia has no direct equivalent to the U.S. FDA Orange Book. The TGA’s ARTG identifies registered therapeutic goods, but it does not provide a comprehensive, statutory patent-listing system equivalent to the U.S. Orange Book.

Patent information may instead be assessed through:

  • Australian patent-register searches.
  • IP Australia records.
  • Public company filings.
  • Court decisions.
  • Patent term calculations.
  • Product information and regulatory submissions.
  • Commercial patent databases.

This fragmented system creates a higher diligence burden for generic sponsors. A product can be TGA-approved without a consolidated public record identifying every patent that may be asserted against launch.

How do Paragraph IV challenges work in Australia?

Australia does not use the U.S. Paragraph IV certification system. Generic applicants do not file an Australian equivalent of a Paragraph IV notice that automatically initiates a defined patent dispute process.

The Australian system instead relies on ordinary patent-law mechanisms. A generic sponsor may:

  • Seek a declaration of non-infringement.
  • Challenge patent validity.
  • Rely on a non-infringement position.
  • Negotiate a license or settlement.
  • Launch at risk after assessing available remedies.
  • Provide commercial notice to the originator before launch.

The Patents Act includes provisions addressing pharmaceutical patent litigation and improper attempts to delay generic competition. The framework does not create an automatic regulatory stay equivalent to the historic U.S. 30-month stay. TGA registration and PBS listing therefore do not automatically stop a generic launch because of a patent dispute.

The practical risk remains significant. An originator may seek interlocutory relief, damages or other remedies if it alleges infringement. Generic companies typically require a documented freedom-to-operate analysis before launch.

Which companies compete in Australia’s branded and generic markets?

Branded and specialty companies

Major originator companies active in Australia include:

  • AstraZeneca.
  • Pfizer.
  • MSD.
  • Novartis.
  • Roche.
  • Sanofi.
  • GSK.
  • Eli Lilly.
  • Boehringer Ingelheim.
  • Bristol Myers Squibb.
  • AbbVie.
  • CSL and CSL Seqirus.

These companies compete in patented medicines, vaccines, specialty care and hospital products. Their Australian strategy often combines direct commercial operations with regional manufacturing, licensing or distribution agreements.

Generic and biosimilar companies

Important generic and biosimilar participants include:

  • Viatris and its legacy Mylan portfolio.
  • Sandoz.
  • Teva.
  • Cipla.
  • Sun Pharma.
  • Aspen.
  • Apotex.
  • Arrotex Pharmaceuticals.
  • Generic products supplied through private-label and pharmacy-owned channels.

Australian generics are frequently manufactured overseas and imported through local sponsors. The local sponsor must manage TGA obligations, pharmacovigilance, recalls, product information, supply continuity and PBS administration.

What opportunities exist for generic and biosimilar companies?

Biosimilars

Australia has one of the more developed biosimilar reimbursement frameworks in the Asia-Pacific region. Biosimilar opportunities are strongest where:

  • The reference biologic has high PBS expenditure.
  • The product has established interchangeability or substitution rules.
  • Hospital procurement supports tender competition.
  • Manufacturing capacity is available.
  • The sponsor can provide reliable cold-chain supply.
  • The product has multiple approved indications.

The main commercial risk is that biosimilar price reductions can be rapid, while development and manufacturing costs remain high. Immunogenicity, device usability, pharmacovigilance and prescriber confidence also affect uptake.

Complex generics

Complex products offer better margins and less immediate competition than standard tablets. Attractive categories include inhalers, depot injections, ophthalmics, modified-release products, sterile injectables and combination devices.

Hospital tenders

Public hospital tenders can create rapid volume access. They also impose strict requirements for price, supply continuity, local support and quality systems. A failed tender can remove a product from a major channel even when the product remains registered.

Local manufacturing and regional supply

Australia has policy support for sovereign manufacturing in selected categories, including vaccines, critical medicines and advanced therapies. Local production can improve government relationships and supply resilience, but Australian operating costs are high relative to Asian manufacturing locations. The strongest model is often regional manufacturing with Australian release, quality, regulatory and distribution capabilities.

Licensing and co-commercialization

Licensing structures are used for:

  • TGA registration rights.
  • PBS commercialization.
  • Local distribution.
  • Hospital tender access.
  • Biosimilar development.
  • Supply of finished dosage forms.
  • In-licensing of specialty products from smaller biotechnology companies.

The principal diligence points are territory scope, regulatory responsibility, minimum purchase obligations, pharmacovigilance, supply guarantees, patent indemnity, price-disclosure treatment and termination rights. A licensee must assess whether discounts and rebates will be reported in a way that reduces future PBS prices.

What challenges face branded drug companies?

Originators face increasing pressure from four mechanisms:

  1. Patent expiry and generic substitution.
  2. PBS reference pricing and statutory reductions.
  3. PBAC cost-effectiveness requirements.
  4. Government measures expanding medicine supply and reducing patient costs.

The 60-day dispensing policy increases the quantity dispensed per prescription for selected chronic medicines. The policy is intended to reduce patient costs and government expenditure, but it changes pharmacy inventory, wholesaler demand, forecasting and manufacturer supply requirements (Australian Government Department of Health and Aged Care, 2023).

For branded products, the policy can reduce prescription frequency and weaken brand engagement. For generics, it can increase volume while intensifying inventory and working-capital demands.

What generic launch risks exist after patent expiry?

A generic launch normally falls into three scenarios.

Launch scenario Conditions Commercial result
Immediate launch Core patent expired; no effective secondary patent; TGA and PBS ready Rapid price and volume competition
Delayed launch Patent dispute, regulatory delay or unresolved listing terms Originator retains share; generic incurs launch costs
At-risk launch Sponsor launches despite asserted patents Potential early revenue but material injunction and damages exposure

The most important diligence questions are:

  • Which Australian patents remain in force?
  • Does the product infringe formulation or process claims?
  • Are method-of-use claims relevant to the proposed label?
  • Is a skinny label commercially workable?
  • Has the originator obtained an interlocutory injunction?
  • Will the generic qualify for PBS substitution?
  • Are there supply or API constraints?
  • Will price disclosure reduce the product’s margin after launch?

A generic company should model both the legal and reimbursement calendars. A launch timed to patent expiry but delayed by PBS administration can lose the first-mover advantage.

How strong is the Australian patent estate for branded medicines?

Patent strength depends on claim breadth, remaining term, validity, infringement evidence and commercial relevance. The strongest estate normally combines a valid compound patent with enforceable formulation, device or manufacturing claims that cover the marketed product.

An estate is weaker when:

  • The compound patent has expired.
  • Secondary claims cover narrow features not used by the generic.
  • The method-of-use indication can be omitted.
  • The patent has prior-art or inventive-step weaknesses.
  • The originator cannot show likely infringement.
  • The product is exposed to multiple generic entrants.
  • The originator has limited ability to obtain interim relief.

Patent term should be assessed separately for each Australian patent family. International patent expiry dates cannot be copied directly into an Australian launch model because filing dates, term extensions, divisional applications and local prosecution history may differ.

What is the outlook for Australian drug-market competition?

Competition will intensify in mature small-molecule categories and selected biologic classes. The highest-value opportunities are likely to remain in oncology, immunology, diabetes, obesity, rare disease, vaccines, hospital injectables and complex delivery systems.

The commercial model is shifting:

  • Originators need stronger evidence packages and narrower, higher-value indications.
  • Generic companies need differentiated supply, complex products and regulatory execution.
  • Biosimilar companies need clinical credibility and substitution access.
  • Licensees need PBS expertise rather than simple distribution capacity.
  • All suppliers need greater control over inventory and product availability.

Australia is attractive as a reference market for regulatory quality, PBS access and regional commercialization. It is less attractive for undifferentiated commodity generics where price disclosure and pharmacy concentration can reduce returns.

Key Takeaways

  • Australia is a PBS-led pharmaceutical market with separate TGA, reimbursement and patent decision points.
  • TGA registration is necessary but does not guarantee PBS access or commercial success.
  • Generic competition is driven by patent expiry, price disclosure, substitution and hospital tenders.
  • Australia has no direct Orange Book or Paragraph IV system.
  • Patent risk extends beyond active ingredients to formulations, methods of use, devices and manufacturing processes.
  • Biosimilars and complex generics offer better strategic opportunities than undifferentiated tablets.
  • The 60-day dispensing policy increases pressure on forecasting, inventory and pharmacy economics.
  • Licensing and co-commercialization agreements must address PBS price disclosure, pharmacovigilance and supply obligations.
  • The strongest market-entry strategies combine patent clearance, TGA execution, PBAC planning and reliable supply.

FAQs

Does Australia grant market exclusivity to new drugs?

Australia generally relies on patents and regulatory data protection rather than a broad standalone market-exclusivity period. Qualifying new active substances commonly receive five years of regulatory data protection, subject to statutory conditions.

Can a generic launch in Australia before all secondary patents expire?

It can launch only after assessing infringement, validity, labeling and litigation risk. Expiry of the active-ingredient patent does not automatically eliminate formulation, device, method-of-use or manufacturing patent exposure.

Are Australian biosimilars automatically interchangeable with the reference biologic?

No. Interchangeability and substitution depend on TGA regulatory decisions and applicable substitution rules. Approval alone does not establish unrestricted pharmacy substitution.

How does the PBS affect the price of generic medicines?

The PBS uses reference pricing, statutory reductions and price disclosure. Effective supplier prices can trigger future reimbursement reductions, compressing generic margins after market entry.

Is Australia a good launch market for a complex generic?

Australia can be attractive when the product has limited competition, strong PBS demand, reliable supply and manageable patent risk. Commodity generics face greater pressure from price disclosure, pharmacy concentration and low reimbursement margins.

References

Australian Government Department of Health and Aged Care. (2023). Budget 2023-24: Strengthening Medicare and cheaper medicines. https://www.health.gov.au/

Australian Government Department of Health and Aged Care. (2024a). Pharmaceutical Benefits Advisory Committee. https://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings

Australian Government Department of Health and Aged Care. (2023). Pharmaceutical Benefits Scheme annual report 2022-23. https://www.pbs.gov.au/

IP Australia. (2024). Patents Act 1990 and pharmaceutical patent term extensions. https://www.ipaustralia.gov.au/

Therapeutic Goods Administration. (2024a). Australian Register of Therapeutic Goods and medicine registration. https://www.tga.gov.au/

Therapeutic Goods Administration. (2024b). Biosimilar medicines. https://www.tga.gov.au/

Therapeutic Goods Administration. (2024c). Priority review and provisional approval pathways. https://www.tga.gov.au/

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.